Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT

Annals of Hematology

Volumn 99, Issue 2, 2020, Pages 343-349

  Meng, Guangqiang ^a   Wang, Jingshi ^a   Wang, Xinkai ^a   Wang, Yini ^a   Wang, Zhao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Acute GVHD; Allogenic stem cell transplantation; Hemophagocytic lymphohistiocytosis; Ruxolitinib

Indexed keywords

ASPARAGINASE MACROGOL; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORINE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RUXOLITINIB; TACROLIMUS; PYRAZOLE DERIVATIVE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL OUTCOME; CYTOMEGALOVIRUS; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN CELL; MALE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS REACTIVATION; YOUNG ADULT; ACUTE DISEASE; ALLOGRAFT; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; EPSTEIN BARR VIRUS INFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; SKIN DISEASE; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOGRAFTS; CHILD; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; EPSTEIN-BARR VIRUS INFECTIONS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; PYRAZOLES; RETROSPECTIVE STUDIES; SKIN DISEASES; STEROIDS; SURVIVAL RATE;

EID: 85077152742     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-019-03864-y     Document Type: Article

References (25)

1. Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, Fischer J, Otten V, Schmickl M, Maas-Bauer K, Finke J, Peschel C, Duyster J, Poeck H, Zeiser R, von Bubnoff N (2014) Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 123(24):3832–3842
2. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068
3. Khandelwal P, Teusink-Cross A, Davies SM, Nelson AS, Dandoy CE, El-Bietar J et al (2017) Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant 23(7):1122–1127
4. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18(4):295–304
5. Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F, Hönigsmann H, Knobler RM (2000) Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 96(7):2426–2431
6. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825–828
7. Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z (2016) PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol 9(1):84
8. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C et al (2012) First-and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 18(8):1150–1163
9. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB et al (2002) Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8(3):155–160
10. Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, Deau-Fischer B, Varet B, Hermine O, Buzyn A (2009) Rapamycin for refractory acute graft-versus-host disease. Transplantation 88(9):1081–1087
11. Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R et al (2010) Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 45(8):1347–1351
12. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, Lee KB (2004) Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 73(1):56–61
13. Furlong T, Martin P, Flowers ME, Carnevale-Schianca F, Yatscoff R, Chauncey T, Appelbaum FR, Deeg HJ, Doney K, Witherspoon R, Storer B, Sullivan KM, Storb R, Nash RA (2009) Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 44(11):739–748
14. Hautmann AH, Wolff D, Hahn J, Edinger M, Schirmer N, Ammer J, Holler B, Landfried K, Hautmann MG, Ahrens N, Ugocsai P, Andreesen R, Holler E (2013) Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE spectra system. Bone Marrow Transplant 48(3):439–445
15. Berger M, Albiani R, Sini B, Fagioli F (2015) Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study. Transfusion 55(4):736–747
16. Ballesteros M, Ferrá C, Serrano D, Batlle M, Ribera JM, Díez-Martín JL (2008) Antithymocyte globulin therapy for steroid-resistant acute graft versus host disease. Am J Hematol 83(10):824–825
17. Schub N, Günther A, Schrauder A, Claviez A, Ehlert C, Gramatzki M, Repp R (2011) Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant 46(1):143–147
18. Schnitzler M, Hasskarl J, Egger M, Bertz H, Finke J (2009) Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 15(8):910–918
19. de Lavallade H, Mohty M, Faucher C, Fürst S, El-Cheikh J, Blaise D (2006) Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 91(10):1438–1440
20. Modi B, Hernandez-Henderson M, Yang D, Klein J, Dadwal S, Kopp E et al (2019) Ruxolitinib as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 25(2):265–269
21. Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, Yu XZ (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115(7):1582–1587
22. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD, Emery VC (1998) Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 21(6):597–605
23. Kröger N (2018) Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran a, Christopeit M, Ayuk F, et al. Peritransplantation Ruxolitinib prevents acute graft-versus-host disease in patients with Myelofibrosis undergoing Allogenic stem cell transplantation. Biol Blood Marrow Transplant 24(10):2152–2156
24. Zandvakili I, Conboy CB, Ayed AO, Cathcart-Rake EJ, Tefferi A (2018) Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience. Am J Hematol 93(5):E123–E125
25. von Bubnoff N, Ihorst G, Grishina O, Röthling N, Bertz H, Duyster J et al (2018) Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). BMC Cancer 18(1):1132